联邦制药发盈喜，预期中期净溢利约为18.5亿元 同比上升

Core Viewpoint - The company expects a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to RMB 1.491 billion for the same period in 2024, indicating a significant increase in profitability driven by licensing fee income from Novo Nordisk [1] Financial Performance - The anticipated net profit increase is primarily attributed to licensing fee income of approximately RMB 1.1 billion from Novo Nordisk [1] - However, there is a decline in segment profits, with intermediate products decreasing by approximately RMB 430 million and raw materials decreasing by approximately RMB 270 million compared to the same period in 2024, partially offsetting the overall profit growth [1]